HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ruben A Mesa Selected Research

Transplantation

10/2020Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.
1/2019Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
8/2011Transplantation for myelofibrosis: time for a randomized trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ruben A Mesa Research Topics

Disease

105Primary Myelofibrosis (Myelosclerosis)
02/2024 - 03/2002
48Neoplasms (Cancer)
02/2024 - 02/2002
35Splenomegaly
04/2021 - 06/2002
31Anemia
11/2023 - 07/2004
29Polycythemia Vera
12/2023 - 08/2002
23Essential Thrombocythemia
01/2023 - 04/2005
19Cytopenia
01/2023 - 08/2002
15Fatigue
11/2023 - 03/2006
14Thrombocytopenia (Thrombopenia)
01/2023 - 07/2004
9Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 07/2005
9Myelodysplastic Syndromes (Myelodysplastic Syndrome)
07/2017 - 08/2003
8Leukemia
01/2021 - 03/2006
8Myeloproliferative Disorders (Myeloproliferative Disorder)
01/2019 - 08/2003
6Fibrosis (Cirrhosis)
01/2021 - 03/2002
5Pain (Aches)
04/2019 - 08/2005
5Disease Progression
05/2017 - 02/2005
4Blast Crisis (Blast Phase)
10/2020 - 09/2012
4Hematologic Neoplasms (Hematological Malignancy)
04/2012 - 02/2002
4Thrombocytosis (Thrombocythemia)
09/2010 - 05/2002
3Thrombosis (Thrombus)
01/2023 - 06/2006
3Philadelphia Chromosome
10/2017 - 07/2011
3Fever (Fevers)
05/2017 - 07/2013
3Polycythemia (Erythrocytosis)
06/2013 - 08/2002
3BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2012 - 06/2007
2Hemorrhage
01/2023 - 01/2017
2Inflammation (Inflammations)
04/2021 - 01/2015
2Lung Neoplasms (Lung Cancer)
01/2020 - 01/2017
2Obesity
01/2020 - 04/2014
2Dyspnea (Shortness of Breath)
04/2019 - 01/2017
2Pruritus (Itching)
04/2019 - 07/2013
2Pneumonia (Pneumonitis)
05/2017 - 01/2017
2Sepsis (Septicemia)
05/2017 - 01/2017
2Nausea
01/2017 - 04/2012
2Diarrhea
01/2017 - 04/2012
2Weight Loss (Weight Reduction)
07/2013 - 11/2011
2Venous Thrombosis (Deep-Vein Thrombosis)
06/2013 - 06/2006
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
03/2012 - 08/2004
2Leukocytosis (Pleocytosis)
09/2009 - 02/2005
2Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
06/2007 - 11/2006
2Portal Hypertension
07/2006 - 08/2005
2Hepatomegaly
02/2006 - 02/2005
2Osteosclerosis
01/2006 - 07/2004

Drug/Important Bio-Agent (IBA)

50ruxolitinibIBA
06/2023 - 09/2009
28Janus Kinase InhibitorsIBA
06/2023 - 01/2013
14N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA
02/2024 - 04/2012
1211- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA
10/2023 - 04/2012
12fedratinibIBA
01/2022 - 09/2009
11Janus KinasesIBA
11/2023 - 03/2012
10Syntex adjuvant formulationIBA
02/2024 - 07/2011
9Hemoglobins (Hemoglobin)IBA
04/2021 - 04/2003
8Thalidomide (Thalomid)FDA Link
01/2011 - 05/2002
6Hydroxyurea (Hydrea)FDA LinkGeneric
12/2022 - 05/2008
6Janus Kinase 2IBA
05/2021 - 03/2008
6Proteins (Proteins, Gene)FDA Link
01/2021 - 08/2008
6Janus Kinase 1IBA
12/2017 - 12/2013
6CytokinesIBA
07/2015 - 05/2002
5Phosphotransferases (Kinase)IBA
01/2020 - 07/2005
5Lenalidomide (CC 5013)FDA Link
04/2012 - 08/2006
5Prednisone (Sone)FDA LinkGeneric
01/2011 - 04/2003
4InterferonsIBA
12/2022 - 05/2011
4pomalidomideIBA
01/2015 - 09/2009
4Imatinib Mesylate (Gleevec)FDA Link
03/2013 - 05/2002
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2007 - 04/2005
3CollagenIBA
01/2021 - 07/2004
3Immunomodulating AgentsIBA
07/2017 - 01/2010
3ErythropoietinFDA Link
01/2013 - 08/2002
3Cytarabine (Cytosar-U)FDA LinkGeneric
03/2012 - 07/2005
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2008 - 03/2002
2activin AIBA
11/2023 - 10/2023
2Danazol (Azol)FDA LinkGeneric
11/2023 - 04/2021
2LigandsIBA
12/2022 - 08/2008
2Telomerase (Telomerase Reverse Transcriptase)IBA
12/2022 - 01/2016
2IronIBA
04/2021 - 01/2015
2DecitabineFDA Link
10/2020 - 12/2018
2CreatinineIBA
10/2017 - 08/2015
2Azacitidine (5 Azacytidine)FDA Link
10/2015 - 01/2015
2Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
04/2014 - 06/2013
2adavosertibIBA
04/2014 - 03/2012
2Heat-Shock Proteins (Heat-Shock Protein)IBA
11/2011 - 07/2005
2tanespimycin (17AAG)IBA
11/2011 - 07/2005
2Checkpoint Kinase 1IBA
11/2011 - 07/2005
217-aminogeldanamycinIBA
11/2011 - 07/2005
2DNA (Deoxyribonucleic Acid)IBA
03/2008 - 11/2006
2Etanercept (Enbrel)FDA Link
08/2002 - 03/2002
1TESIBA
12/2023
1Activin Receptors (Activin Receptor)IBA
10/2023
1HepcidinsIBA
10/2023
1luspaterceptIBA
12/2022
1PRM-151IBA
12/2022
1navitoclaxIBA
12/2022

Therapy/Procedure

76Therapeutics
06/2023 - 02/2002
8Stem Cell Transplantation
11/2019 - 08/2003
6Erythrocyte Transfusion
12/2017 - 07/2004
4Drug Therapy (Chemotherapy)
12/2014 - 05/2003
4Splenectomy
07/2006 - 05/2003
3Cell Transplantation
10/2020 - 11/2015
3Transplantation
10/2020 - 08/2011
3Radiotherapy
12/2018 - 10/2003
3Immunomodulation
12/2013 - 09/2009
2Hematopoietic Stem Cell Transplantation
01/2019 - 02/2006